Navigation Links
Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting

D1 Sunday, June 3, 2007 at 8:00 a.m. to 12:00 p.m. - Poster Discussion Presentation Session Title: Gynecologic Cancer Abstract No. 5516 "A Phase 2 trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer" Presenter: Nicoletta Colombo, M.D. Location: Display - E415a (Board 6), Discussion - E354a (11:00 am to 12:00 pm) Sunday, June 3, 2007 at 2:00 p.m. to 6:00 p.m. - Poster Presentation Session Title: Sarcoma Abstract No. 10076 "Survival results with AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue or bone sarcomas: Update of Phase 2 trial" Presenter: Sant P. Chawla, M.D. Location: Display - S Hall A2 (Board JJ4)

About AP23573

ARIAD's lead product candidate, AP23573, is a novel small-molecule inhibitor of the protein mTOR, a "master switch" in cancer cells. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis. AP23573 is currently in Phase 1 and 2 clinical trials in patients with solid tumors and hematologic cancers. AP23573 has been designated both as a fast-track product and an orphan drug by the U.S. Food and Drug Administration and as an orphan drug by the European Medicines Agency for the treatment of soft-tissue and bone sarcomas. In addition to its program in oncology, ARIAD is collaborating with Medinol Ltd to develop stents and other medical devices that deliver AP23573 to prevent reblockage at sites of vascular injury following stent-assisted angioplasty.

About ARIAD

ARIAD is engaged in the discovery and development of breakthrough medicines to treat cancer by regulating cell signaling with small molecules. The Company is developing a comprehensive approach to patients with cancer that addresses the greatest medical need - aggressive and advanced-stage cancers for which current treatments are inadequate. Medinol Ltd. also is developing stents and other medical devices that d
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:1/15/2014)... today announced it has established a relief fund ... that has gripped much of the nation. AARP and its ... support these emergency relief efforts AARP and AARP Foundation will ... to $500,000 in aid. The matching program will be administered ...
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
(Date:4/22/2014)... spending, a new RAND study concludes that U.S. policy ... and device makers to develop products that produce more ... their use, a new study suggests the study identifies ... created in the first place. The aim is to ... of health as possible and to ensure that costlier ...
(Date:4/22/2014)... researchers have demonstrated the first size-based form of ... membranes of living cells. This unique physical approach ... critical to whether a cell lives or dies, ... obtained through conventional microscopy. , "We,ve developed membrane-embedded ... to both probe and manipulate membrane assemblies, including ...
(Date:4/22/2014)... been approved since November 2013 for the prevention and ... an early benefit assessment pursuant to the "Act on ... the German Institute for Quality and Efficiency in Health ... an added benefit over the appropriate comparator therapy. ... turoctocog alfa is not proven. As no relevant study ...
(Date:4/22/2014)... chronic inflammatory disorders of the intestine that result in ... in the U.S., and while there are treatments to ... , Now, Cincinnati Cancer Center and University of Cincinnati ... in her lab have done what is believed to ... important function for the Ron receptor, a cell surface ...
(Date:4/22/2014)... of us have gotten stuck in a check-out line ... Mather, assistant professor of physics and an instructor with ... or queues, has been crucial in trying to understand ... of proteins. , The work, submitted during Mather,s first ... the National Science Foundation in the form of a ...
Breaking Medicine News(10 mins):Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:First size-based chromatography technique for the study of livi 2Health News:First size-based chromatography technique for the study of livi 3Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 2Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 3Health News:Two genes linked to inflammatory bowel disease 2Health News:Queuing theory helps physicist understand protein recycling 2
... 15 Theranostics Health (THX) today,announced that ... research,collaboration agreement with Duke University. This relationship ... core technologies: Laser,Capture Microdissection (LCM) and Reverse ... these technologies provides a powerful,mechanism to accurately ...
... Corporation, a,subsidiary of Orthopedic Development Corporation, announced today ... treat chronic facet-oriented back,pain or to supplement other ... of the two facet joints in each spinal ... treat intractable back pain without,precluding other options, has ...
... Health Solutions, Corp.,("SXC" or the "Company") (NASDAQ: SXCI ... services, announces that Mark Thierer,President and COO and Jeff ... Capital Markets 12th Annual Spring Investor Conference at the ... on Thursday, May 29,2008 at 10:30 am Eastern Time., ...
... important as intervention, specialists say , , THURSDAY, May 15 ... such as pacemakers and defibrillators emphasize that they,re just ... very specific statement of the importance of optimized medical ... University of Alabama at Birmingham,s Division of Cardiovascular Disease, ...
... American College of Physicians (ACP) proposed today a ... and use of information about clinical and cost-effectiveness ... The recommendations are featured in an article, Cost-Effectiveness ... Effectiveness Entity, published online today in Annals of ...
... BIRMINGHAM, Ala., May 15 Diagnostic Health Corporation,(DHC), ... the appointment of Robert E. Gontarek as its ... this role, Gontarek will oversee,the operations of DHC,s ... Gontarek joins DHC with nearly 20 years ...
Cached Medicine News:Health News:Theranostics Health Signs Research Collaboration Agreement 2Health News:TruFUSE(R) Minimally Invasive Facet Fusion Procedure Tops 3,000 Spinal Levels 2Health News:New Guidelines Issued for Implanted Heart Devices 2Health News:Americans must consider cost and effectiveness when comparing and choosing medical interventions 2Health News:Diagnostic Health Corporation Names Robert E. Gontarek as COO 2
... A stethoscope adapter for users of ... and socket" type - must send ... are required. , ,Westone custom ... via our worldwide network of hearing ...
... bronchoscopy: The HF-compatible V series from Pentax, ... bronchoscopes are measured., ,The HF-compatible series ... FB-19TV, FB-18V and FB-15V models along with ... FB-8V, offer much better image quality thanks ...
... from the latest 60 series bronchoscopes., ... range, focussing on providing clinicians with ... Olympus has a impressive range of ... in the respiratory tract to meet ...
Extra-large 3.2mm channel allows excellent suction with EndoTherapy devices in place....
Medicine Products: